Literature Review

Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?

Volume 10 · Issue 1 Publish Date: March 7, 2023
Full Text PDF
DOI
Yiannis Ioannou
UCB Pharma, Slough, UK
Timothy Beukelman
Epi Excellence LLC, Garnet Valley, PA, USA
Miranda Murray
UCB Pharma, Slough, UK
Doruk Erkan
Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, New York, USA
Ioannou, Y., Beukelman, T., Murray, M., & Erkan, D. (2023). Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?. European Journal of Rheumatology, 10(1), 39–44. https://doi.org/10.5152/eurjrheum.2023.22012
Full Text Full Text PDF

Abstract

Antiphospholipid syndrome is a systemic autoimmune disorder characterized by vascular thrombosis and/or obstetric events in association with persistently elevated antiphospholipid antibodies. Antiphospholipid syndrome is typically considered a rare disease, but the true incidence is uncertain owing to the diverse antiphospholipid antibody-related clinical manifestations, inconsistent definitions of antiphospholipid antibody positivity, under-recognition of the disease, and limited population-based studies. Published estimates of the incidence of antiphospholipid syndrome range from approximately 2 to 80 per 100 000 person-years. A targeted literature review and applied methodology were performed to derive a best available estimate. Significant limitations of the published literature were observed, some of which have been previously reported. The incidence of antiphospholipid syndrome in the United States was estimated to be approximately 7.1 to 13.7 per 100 000 person-years in the general population. Although this estimate is likely more accurate than previously reported estimates, large, contemporary, population-based studies that reasonably adhere to the antiphospholipid syndrome classification criteria are needed to further refine estimates of the incidence of antiphospholipid syndrome.

Cite this article as: Ioannou Y, Beukelman T, Murray M, Erkan D. Incidence of antiphospholipid syndrome: Is estimation currently possible? Eur J Rheumatol. 2023;10(1):39-44.

Article Info
Published In
Journal European Journal of Rheumatology
Volume / Issue Volume 10 · Issue 1
Pages 39-44
History
Published Online March 7, 2023
Copyright
Affiliations
Yiannis Ioannou
UCB Pharma, Slough, UK
Timothy Beukelman
Epi Excellence LLC, Garnet Valley, PA, USA
Miranda Murray
UCB Pharma, Slough, UK
Doruk Erkan
Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, New York, USA
Cite this Article
Ioannou, Y., Beukelman, T., Murray, M., & Erkan, D. (2023). Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?. European Journal of Rheumatology, 10(1), 39–44. https://doi.org/10.5152/eurjrheum.2023.22012
Share
Outlines